<DOC>
	<DOCNO>NCT01777646</DOCNO>
	<brief_summary>The study evaluate safety , tolerability therapeutic effect transplantation escalate dos autologous culture mesenchymal bone marrow stromal cell secrete neurotrophic factor ( MSC-NTF ) , patient amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors ( MSC-NTF ) , Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This phase IIa prospective , open label , dose-escalating , three patient-group clinical study , evaluate safety , tolerability preliminary efficacy autologous culture mesenchymal bone marrow stromal cell secrete neurotrophic factor ( MSC-NTF ) , potent treatment patient Amyotrophic Lateral Sclerosis ( ALS ) early disease stage . This study single center trial . It anticipate study conduct Department Neurology &amp; Laboratory Neuroimmunology , Hadassah Hebrew University Medical Center , Jerusalem Israel . In addition , ALS patient could also refer clinical site medical center . All patient enrol documented history ALS disease prior study enrollment . Patients diagnose early stage ALS disease duration le 2 year . ALS patient identify `` predisposed '' approach request sign Informed Consent Form ( ICF ) . Overall , 14 patient recruit . Treatment start low dose ( 94x106 cell ) dose increase next medium high dose ( 141x106 188x106 respectively ) , next patient group follow safety analysis . The expected duration patient screen period prior enrollment study in-between two week 2 day prior study enrollment day visit 2 ( verification compliance inclusion/exclusion criterion include clinical laboratory result ) . Eligible patient enrol study observe every month `` run period '' 3 month determination progression rate disease ( allow time window ± 5 day visit ) . During `` run period '' 6 week follow enrollment , patient study group undergo Bone Marrow Aspiration ( BMA ) procedure MSC-NTF cell produce bone marrow aspirate base Brainstorm Cell Therapeutics Ltd proprietary method . On last `` run period '' visit , patient undergo treatment MSC-NTF transplant IM+IT early ALS patient . After MSC-NTF transplantation patient observe monthly basis post treatment follow period 6 month ( allow time window ± 5 day visit ) . Treatment safety , adverse event exploratory parameter , establish ALS progression rate assessment disease record throughout duration `` run period '' post treatment follow period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Patient must fulfill El Escorial criterion ( APPENDIX 2 ) definite probable ALS ( sporadic familial ) 2 . Participants , either men non pregnant woman 20 75 year age . 3 . The patient mentally intact psychologically stable 4 . Patients ALSFRSR scale ( APPENDIX 3 ) least 30 disease duration le 2 year . 5 . Patient sufficiently bulky muscle . 6 . Participant understands nature procedure provide write informed consent prior study procedure . 1 . Patient positive test HBV , HCV HIV . 2 . Patient high protein CSF ( Protein &gt; 70 mg/ml ) . 3 . Patient lymphocytosis CSF ( lymphocytes &gt; 5/ml ) . 4 . Patient positive antiGM1 antibody . 5 . Patient significant conduction block slow nerve conduction velocity ( reduction 30 % ) confirm nerve conduction velocity EMG study . 6 . The patient respiratory dependent patient . 7 . Patients renal failure ( Cr &gt; 2 mg/dl ) . 8 . Patients impaired hepatic function ( ALT , AST GGT 2fold high normal upper limit ) . 9 . Patients suffer significant cardiac disease , malignant disease disease may risk patient interfere ability interpret result 10 . Patient active infection . 11 . Participation another clinical trial within 1 month prior start study . 12 . Patient treat previously cellular therapy . 13 . Subject unwilling unable comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Mesenchymal Strmal Cells ( MSC )</keyword>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Neurodegeneration</keyword>
	<keyword>Stem cell</keyword>
</DOC>